DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 70-027

Sidmak Laboratories, Inc.
Attention: Dr. Satish P. Patel
17 West Street
P. O. Box 371
East Hanover, New Jersey 07936

DEC - 6 1984

Gentlemen:

Please refer to your abbreviated new drug application dated April 25, 1984, submitted pursuant to Section 505(b) of the Federal Food, Drug, and Cosmetic Act for Metronidazole Tablets, USP 250 mg.

Reference is also made to your communication dated September 17, 1984 and November 29, 1984.

We have completed the review of this abbreviated new drug application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved.

Any significant change in the conditions outlined in this abbreviated new drug application requires an approved supplemental application before the change may be made, except for changes made in conformance with other provisions of Section 314.8 of the new drug regulations.

This Administration should be advised of any change in the marketing status of this drug.

For Initial Campaigns: We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your immediate advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Advertising and Labeling (HFN-240). Also, please do not use Form FD-2253 for this submission.

For Subsequent Campaigns: We call your attention to Regulation 21 CFR 310.300(b)(3) which requires that all material for any subsequent advertising or promotional campaigns at the time of their initial use be submitted to our Division of Drug Advertising and Labeling (HFN-240) with a completed Form FD-2253. A copy of Form FD-2253 is enclosed for your convenience.

The enclosures summarize the conditions relating to the approval of this application.

Sincerely yours,

Marvin Seife, M.D.
Director
Division of Generic Drugs
Office of Drug Standards
Center for Drugs and Biologics

Enclosures:
Conditions of Approval of a New Drug Application
Records & Reports Requirements
Form FD 2253

NDA 70-027

A FULL STATEMENT OF THE COMPOSITION OF THE DRUG:

Metronidazole Tablets - 250 mg

Ingredient	mg/Tablet
Metronidazole, USP	255.00*
Microcrystalline Cellulose, NF	83.50
Crospovidone, NF	12.50
Colloidal Silicon Dioxide, NF	2.00
Hydrogenated Vegetable Oil, NF	7.00
TOTAL TABLET WEIGHT	360.00

*Includes a 2% excess.

Supplier of the active ingredient:

Farchemia S.p.A.
Treviglio, Italy